Key Events This Week
20 Jul: Stock surges 6.51% on strong volume
21 Jul: Continued gains with 1.60% rise and steady delivery volumes
22 Jul: Minor dip amid broader market weakness
23 Jul: New 52-week and all-time high reached intraday at Rs.1,777.5
24 Jul: Week closes at Rs.1,647.25, down 1.30% on the day
Monday, 20 July 2026: Strong Opening Rally
Novartis India Ltd began the week with a robust gain of 6.51%, closing at Rs.1,672.55 on volume of 5,642 shares. This surge was notable as it occurred despite a flat Sensex, which closed marginally down by 0.00% at 36,504.94. The strong buying interest set a positive tone for the week, reflecting renewed investor confidence following recent financial disclosures.
Tuesday, 21 July 2026: Continued Momentum and Delivery Volumes
The stock extended gains by 1.60% to close at Rs.1,699.35, supported by increased volume of 6,628 shares. Delivery volumes remained healthy, with 23.06 thousand shares delivered, representing 39.81% of total volume, slightly below the 5-day average delivery percentage of 34.95%. The Sensex edged up 0.04% to 36,518.28, but Novartis India clearly outperformed, consolidating its upward trajectory.
Wednesday, 22 July 2026: Minor Correction Amid Market Weakness
Novartis India Ltd experienced a slight decline of 0.02%, closing at Rs.1,699.05 on lower volume of 4,434 shares. The broader market was weaker, with the Sensex falling 0.88% to 36,196.43. This minor pullback was a pause in the rally, possibly reflecting profit-taking after two consecutive days of gains. The stock remained well above key moving averages, maintaining a bullish technical stance.
Thursday, 23 July 2026: New 52-Week and All-Time Highs Amid Mixed Intraday Volatility
On 23 July, Novartis India Ltd reached a significant milestone by hitting an intraday high of Rs.1,777.50, setting both a new 52-week and all-time peak. Despite closing lower at Rs.1,668.95 (-1.77%), the stock outperformed the Sensex which declined 0.70% to 35,944.66. The day was marked by heightened volatility, with the stock swinging between Rs.1,640 and Rs.1,777.50, reflecting active trading and dynamic price discovery.
This milestone was supported by an upgrade in the company’s quality grade from average to good, reflecting strong financial fundamentals such as a high return on capital employed (36.34%) and improved operational efficiency. The company also reported a strong quarterly turnaround with record revenues and margin expansion, signalling renewed growth momentum despite some short-term profit margin pressures.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Friday, 24 July 2026: Week Closes with a Slight Decline
The stock closed the week at Rs.1,647.25, down 1.30% on the day with volume of 4,012 shares, while the Sensex declined 0.32% to 35,829.46. Despite the day’s loss, the stock ended the week with a strong 4.90% gain from the previous Friday’s close of Rs.1,570.30, significantly outperforming the Sensex’s 1.85% decline. The week’s price action reflected a consolidation phase after the midweek highs, with investors digesting the recent strong quarterly results and quality upgrades.
Weekly Price Performance: Novartis India Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-07-20 | Rs.1,672.55 | +6.51% | 36,504.94 | -0.00% |
| 2026-07-21 | Rs.1,699.35 | +1.60% | 36,518.28 | +0.04% |
| 2026-07-22 | Rs.1,699.05 | -0.02% | 36,196.43 | -0.88% |
| 2026-07-23 | Rs.1,668.95 | -1.77% | 35,944.66 | -0.70% |
| 2026-07-24 | Rs.1,647.25 | -1.30% | 35,829.46 | -0.32% |
Key Takeaways from the Week
Strong Relative Performance: Novartis India Ltd outperformed the Sensex by a wide margin, gaining 4.90% versus the index’s 1.85% decline, highlighting the stock’s resilience amid broader market weakness.
Milestone Highs: The stock achieved a new 52-week and all-time high intraday price of Rs.1,777.50 on 23 July, underscoring strong investor interest and positive technical momentum.
Quality Upgrade: The company’s quality grade was upgraded from average to good, reflecting improved profitability, conservative debt levels, and operational efficiency, supported by a high ROCE of 36.34% and robust EBIT growth.
Quarterly Financial Turnaround: Record quarterly revenues of Rs.103.81 crores and margin expansion to 33.63% operating profit margin marked a significant turnaround, with net profit rising to Rs.32.21 crores and EPS reaching Rs.13.05.
Short-Term Volatility and Profit Margin Pressure: Despite strong top-line growth, the company reported a 13.8% decline in quarterly PAT and a drop in operating profit to net sales ratio to 22.77%, signalling some margin pressure that warrants monitoring.
Thinking about Novartis India Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this small-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Conclusion
Novartis India Ltd’s performance during the week of 20–24 July 2026 was characterised by strong gains and significant milestones, including new 52-week and all-time highs. The stock’s outperformance relative to the Sensex reflects robust underlying fundamentals, highlighted by a quality grade upgrade and a strong quarterly turnaround with record revenues and margin expansion. While short-term profit margin pressures and volatility were evident, the company’s conservative capital structure, high return on capital employed, and improved operational efficiency provide a solid foundation for sustained momentum. Investors should continue to monitor margin trends and market conditions, but the week’s developments reinforce Novartis India Ltd’s position as a resilient small-cap player within the Pharmaceuticals & Biotechnology sector.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
